[Correspondence] Management of brain arteriovenous malformations – Authors' reply

ARUBA is the first-ever randomised controlled trial comparing clinical outcome in patients with unruptured brain arteriovenous malformations managed either with or without preventive interventional therapy. The as-treated analysis showed a more than 5-fold increased risk of primary outcome events (ie, death or symptomatic stroke) for patients undergoing invasive therapy (hazard ratio 5·26, 95% CI 2·63–11·11), as well as a significantly increased risk of, at times, devastating neurological deficits after intervention (relative risk 2·77, 95% CI 1·20–6·25).

Source: LANCET - May 9, 2014 Category: Journals (General) Authors: Christian Stapf, Michael K Parides, Alan J Moskowitz, J P Mohr Tags: Correspondence Source Type: research